Last reviewed · How we verify
OxyNEO®
OxyNEO is an extended-release formulation of oxycodone designed to deter abuse by resisting crushing, dissolving, and extraction while maintaining analgesic efficacy.
OxyNEO is an extended-release formulation of oxycodone designed to deter abuse by resisting crushing, dissolving, and extraction while maintaining analgesic efficacy. Used for Moderate to severe pain requiring around-the-clock opioid therapy.
At a glance
| Generic name | OxyNEO® |
|---|---|
| Also known as | Oxycodone |
| Sponsor | Centre for Addiction and Mental Health |
| Drug class | Opioid analgesic, abuse-deterrent formulation |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
OxyNEO uses a proprietary polymer matrix technology that makes the tablet resistant to physical and chemical manipulation, reducing the potential for misuse via snorting or injection. The formulation maintains the pharmacokinetic profile of oxycodone as a mu-opioid receptor agonist for pain relief while adding abuse-deterrent properties. This approach aims to reduce diversion and non-medical use while preserving therapeutic benefit for legitimate pain management.
Approved indications
- Moderate to severe pain requiring around-the-clock opioid therapy
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OxyNEO® CI brief — competitive landscape report
- OxyNEO® updates RSS · CI watch RSS
- Centre for Addiction and Mental Health portfolio CI